The lies we tell other people are nothing to the lies we tell ourselves.”? Derek Landy
This week’s covered call opportunity is around a small biotech concern with a slew of upcoming trial readouts in the second half of 2020. A full analysis and investment recommendation follows in the paragraphs below.
Company Overview
Ovid Therapeutics (OVID) is a New York-based biopharmaceutical company that IPO’d in 2017. The company is focused on developing therapeutics for rare neurological diseases. The company’s most advanced product candidate is OV101, which is currently in development for the